300109.SZ Stock Analysis
30
Neutral
Based on Eyestock quantitative analysis, 300109.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Boai NKY Medical Holdings Ltd. engages in the operation of pharmaceutical excipients, polyvinylpyrrolidone series products and vinyl methyl ether and maleic anhydride polymer products. The company is headquartered in Jiaozuo, Henan and currently employs 992 full-time employees. The company went IPO on 2010-08-25. The Company’s main products include GBL, 2- pyrrolidone, N-vinylpyrrolidone (NVP) monomer, PVP-K series (PVPK), polyvinylpolypyrrolidone (PPVP), PVP- Iodine (PVP-I), related pharmaceutical intermediates and others. The firm's products are mainly used in daily chemical, medicine, liquor and beverage, pigments and coatings, textile, paper making, oil extraction, sensitive material, electronic and other industries. The firm distributes its products in domestic market and to overseas markets.